We have been fortunate to complete two financings in recent months. We believe that these two financings together have provided enough capital to support TTX-MC138's Phase I clinical trial and company ...

BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it ...

BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a ...

TransCode Therapeutics ( ($RNAZ) ) has shared an announcement. At the 2025 Annual Meeting of Stockholders held on August 29, 2025, TransCode ...

The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode's pipeline of RNA-targeted oncology therapeutic and ...

RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncology Dr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and ...

HOUSTON and BOSTON― The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode’s pipeline of RNA-targeted oncology ...

Transcode Therapeutics shares are trading lower by 62% during Tuesday's session. The company announced pricing of its public offering. Our government trade tracker caught Pelosi’s 169% AI winner.